Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 4/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | CDC25C | P30307 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562421 | 0.89 | PSEN1 (0.40) | GRIA1PDE3BPDE3ANPC1RAB9A | |
| SCHEMBL12289961 | 0.86 | PDE3B (0.41) | GRIA1CACNG8PDE3BPDE3ACDC25A | |
| SCHEMBL12287262 | 0.85 | MAPT (0.40) | GRIA1CACNG8PDE3BPDE3ACDC25A | |
| SCHEMBL12287060 | 0.84 | DYRK1A (0.35) | GRIA1CACNG8PDE3BPDE3ACDC25A | |
| SCHEMBL12287887 | 0.83 | PSEN1 (0.40) | NPC1RAB9AIL1B | |
| SCHEMBL12287625 | 0.81 | PSEN1 (0.36) | GRIA1NPC1RAB9AMAPTGAA | |
| SCHEMBL21170107 | 0.77 | NPC1 (0.34) | KCNA5NPC1RAB9AUSP2TP53 | |
| SCHEMBL12287324 | 0.74 | PPM1D (0.48) | GRIA1CACNG8PDE3BPDE3ANPC1 | |
| SCHEMBL29437825 | 0.74 | PIK3CB (0.46) | PDE3BPDE3AMAPTGAADYRK1A | |
| SCHEMBL22191709 | 0.74 | PIK3CB (0.46) | PDE3BPDE3AMAPTGAADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604965-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2015-11-12 | — | — | US | claimed |
| EP-3127541-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10076519-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | CYTOKINETICS INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | CYTOKINETICS INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-9604965-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604965-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-3127541-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | Cytokinetics, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-2563365-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2015-11-12 | — | — | US | disclosed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. | 2013-06-06 | — | — | US | disclosed |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. | 2013-06-06 | — | — | US | disclosed |
| WO-2011133882-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | MUSK, PYGM, GYS1 | KCNA5 400/4885GRIA1 971/4885CACNG8 3540/4885 |
| US-10076519-B2 | Substituted pyridazines as skeletal muscle modulators | MUSK, PYGM, GYS1 | KCNA5 400/4885GRIA1 971/4885CACNG8 3540/4885 |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | SLC7A1, F12, C5 | KCNA5 351/4885GRIA1 813/4885CACNG8 4133/4885 |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, F12, C5 | KCNA5 334/4885GRIA1 753/4885CACNG8 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.